Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.